A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma
- 6 June 2012
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 4 (137), 137ra75
- https://doi.org/10.1126/scitranslmed.3003643
Abstract
Extensively validated tumorgraft model shows activity of investigational agent dovitinib against renal cell carcinoma.Keywords
This publication has 71 references indexed in Scilit:
- Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney TumorCell, 2012
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Regulation of TFEB and V-ATPases by mTORC1The EMBO Journal, 2011
- Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft modelBritish Journal of Cancer, 2011
- Hypoxia-Inducible Factors and the Response to Hypoxic StressMolecular Cell, 2010
- Genome remodelling in a basal-like breast cancer metastasis and xenograftNature, 2010
- The landscape of somatic copy-number alteration across human cancersNature, 2010
- Genome‐wide profiling of chromosomal alterations in renal cell carcinoma using high‐density single nucleotide polymorphism arraysInternational Journal of Cancer, 2009
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Genetics and epigenetics of renal cell cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2008